Form D · Biotechnology
AdvanDx, Inc.
Woburn, MA · CIK 0001561190
Offering snapshot reported Mar 17, 2015 · SEC filing
- Reported sold
- $2.5M Offering amount: $2.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 27, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2015 | Initial | $2,500,000 | No comparison | 2 | SEC filing |
| Apr 8, 2014 | Initial | $9,074,963 | No comparison | 4 | SEC filing |
| Oct 26, 2012 | Initial | $2,166,769 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-236053
Source: Form D, filed Mar 17, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hans Andreasson | Director |
| Thierry Bernard | Director |
| James M. Coull | Executive |
| Heiner Dreismann | Director |
| Christopher D. Earl | Director |
| Roger D. Graham, Jr. | Executive |
| Donald B. Hawthorne | Executive |
| Thomas P. Kelly | Executive |
| Dennis H. Langer | Director |
| David M. Rubin | Director |
| Ingelise Saunders | Director |
| Lars Tonnesen | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
400 Tradecenter, Suite 6990
Woburn, MA, 01801
Woburn, MA, 01801